47 Seed Biotech Investors — 45 Currently Deploying

Invest first in founders making mutants a reality by reimagining the universe. Generalist investors backing companies that make 1 billion lives better through bold bets in deep tec…

Accelerating AI-native founders at the earliest stages. Lead early rounds in companies and founders building the future, providing that first check before others think you're onto …

Thesis-driven early-stage firm backing visionary founders building technologies of the future in Vertical AI, Deep Tech, Health, and Bio with strong data moats and Systems of Recor…

Champion inspired and obsessive builders across seed stage, from enterprise SaaS to sustainability, health, hard tech, AI, infrastructure, consumer, and crypto. Provide guidance fr…

Back European founders with strong qualities (not CV/pedigree) building businesses for a better human future, assessed on characteristics like productivity, grit, and commercial ac…

Petri develops pre-seed companies attacking the world's largest problems at the frontier of biology and engineering, believing the future of biotech is founder-led.

Turn sci-fi into sci-fact by championing companies at the intersection of the new and not-yet-imagined, looking decades into the future to create a world most can barely imagine.

Bold, early, impactful ventures with brutal honesty. Believe in world-class teams making contrarian bets on impossibly big ideas, from AI to cleantech to deep tech.

NFX identifies and backs founders building companies with network effects. The fund emphasizes software development, founder support through content/tools, and emerging technologie…

Compound invests in deep technology across AI/ML, robotics, biology, crypto, and company building. Focus on frontier tech with venture-scale commercial potential and narrative-driv…

Noetic invests in early-stage technologies addressing mental health and wellbeing through novel drug therapeutics, psychedelic-assisted therapies, digital health, medical devices, …

Experienced founders (particularly serial/exit founders) win 22x more often. Zero-equity retreats attract elite repeat founders who avoid traditional accelerators, enabling first-m…

A fund of 500+ Y Combinator alumni investing in and supporting top startups from Y Combinator, the world's top accelerator.

Investing in dreams at the earliest stage, backing founders across marketplaces, fintech, developer tools, frontier tech, climate, and experimental ideas.

Seed and early-stage venture capital firm investing in digital solutions that transform essential, broad-impact industries like healthcare and energy by bringing emerging technolog…

Partner at inception with technically brilliant founders who see past impossible to inevitable. Invest in technical breakthroughs becoming world-changing companies, particularly in…

The Engine is a nonprofit incubator and accelerator dedicated to providing early-stage Tough Tech companies with critical infrastructure, programs, and ecosystem support to help th…

Build world-class technology companies anywhere by leveraging local talent, customers, and strengths. Provide convicted, honest investors who push founders to be great rather than …

Equitable venture capital model where every founder backed becomes a co-owner of the fund. Early-stage investments in mission-driven, pre-seed and seed founders who are outliers, o…

Investing in entrepreneurs building infrastructure and value chains around data, from the full data stack (infrastructure to applications) with belief that accurate, actionable dat…

Founder-driven investing focused on bold teams and transformative ideas. Hands-on approach informed by past lives as founders and operators.

Invest in innovative founders tackling the world's complex challenges, partnering early to help transform ideas into world-class companies.

Deep tech venture capital backing brilliant entrepreneurs addressing the hardest, highest-stakes problems in the world, using AI to unlock potential across sectors.

Correlation Ventures backs groundbreaking technology and data science companies that solve industry problems through rapid decision-making and industry-leading networks.

Expa is a Company Studio that takes companies from 0 to 10,000. The fund provides capital, talent, and operational support to build and scale companies from inception.

Early-stage venture firm investing in technical founders solving hard engineering and science problems through the 'Super Evolution' — a non-linear approach to innovation enabled b…

Support domestic and international startups through capital provision and business collaboration, leveraging Dentsu Group's creative and strategic resources alongside global VC net…

Speedinvest provides European startups with 'more expertise, connections, reach, and momentum' through specialist investment teams across six core sectors, backing companies from s…

Network-driven early stage venture capital firm with a generalist approach and sub-focus on deep tech, bringing exceptional value to founders through proprietary 'Friends of Fitz' …

Partner early with founders building enduring companies with conviction before consensus, often being the first check from pre-seed to seed stage.

Multi-stage venture capital firm that goes beyond traditional VC playbook by providing entrepreneurs support of a global ecosystem, connecting innovators everywhere.

Pre-Seed and Seed investors partnering with visionary founders. We believe Artificial Intelligence will disrupt every industry.

We invest in founders who build differently and create technology that serves humanity. We protect fragile ideas from the offline world until they're ready to scale.

Partner with exceptional people to help them realize their full potential across pre-seed, seed, growth, and public market stages through long-term founder relationships.

Backing mission-driven, outlier founders at pre-seed and seed stage across UK, Europe and North America through generalist and institutional thesis-driven funds.

Early-stage tech investments in the US and Israel, providing access and meaningful connections to help brilliant minds breakthrough.

Building breakthrough biotechs through partnerships with world-class life science entrepreneurs, translating groundbreaking science into life-changing medicines over 30+ years.

Back founders on a mission to industrialize scientific and technological progress.

Support game-changing, early-stage Canadian technology leaders building the future by believing that people, not money, build great companies and supporting founders from day one.

Supporting entrepreneurs who follow their passion, with explicit focus on founders from underserved communities and diverse backgrounds (female, immigrant, underrepresented).

A talent and research-driven investment firm that identifies and invests in a small number of entrepreneurs and companies they build, from seed to scale.

Supporting ambitious founders to build category defining companies

Deep tech and hardware-focused accelerator investing in frontier technologies with global reach

Every founder deserves an equal opportunity to scale their business. We look for great teams who have the ability to capture a compelling market opportunity. We invest in high grow…

Blue Ivy Ventures provides Yale alumni accredited investors access to diversified venture capital investments co-invested alongside leading VC firms, combining a curated annual fun…

Partner with entrepreneurs from early days through every stage of growth, focusing on transformative technology across AI/ML, biotech, cloud, consumer, and crypto sectors.

How many seed biotech investors are actively deploying right now?

DryPowder tracks 47 seed biotech funds. Of these, 45 are currently deploying capital based on recent fund closes, portfolio activity, and partner signals. Use DryPowder's fund matching to see which ones fit your specific startup.

What check size do seed biotech VCs write?

Among 47 seed biotech funds on DryPowder, check sizes run from $50K–$50M. Ranges vary by fund size, vintage, and whether the fund leads rounds. Each fund profile shows check size detail and lead preference.

How do I get a meeting with a seed biotech VC?

A warm intro is still the fastest path. Most seed biotech VCs on DryPowder do accept cold outreach or direct applications, but response rates vary widely by fund. Before reaching out, use DryPowder's AI matching to get a fit score and specific talking points. Founders who lead with thesis-aligned framing get significantly better response rates than those sending the same deck to every fund on a list.

How long does a seed round typically take to close?

Seed rounds typically take 3-6 months from first meeting to close. Most of that time is spent on qualification: investors want to see early traction, run multiple meetings, and often complete reference checks. With a committed lead who sets terms, the rest of the round usually fills within 2-4 weeks. Without a lead, the process drags. DryPowder's deployment signals help identify which seed funds are actively writing checks right now versus sitting between vehicles.

How many seed biotech investors should I be talking to at once?

Most fundraisers recommend a parallel process: identify 20-40 target investors but approach your highest-fit funds first. Of the 45 seed biotech funds currently deploying, not all will match your specific stage and sector. Use fund matching to find your top 10-15, approach those first, collect feedback, then go wider. Going to every fund simultaneously without qualifying first burns bridges and dilutes the urgency that helps close a round.

How is DryPowder different from building a VC list on LinkedIn or Crunchbase?

The fund list you build on LinkedIn or Crunchbase is roughly the same list every other founder is building. DryPowder adds three things a manual search cannot: deployment signals (which funds have recently closed new vehicles and are actively writing checks), AI thesis matching (which of the 47 seed biotech funds actually fits your specific startup, ranked by fit), and verified partner contact details. The goal is 15 targeted, thesis-aligned pitches instead of 150 generic ones.